2024 Ohio Law Review Katie Stabi, PharmD, BCPS, RPh Compliance Specialist State of Ohio Board of Pharmacy





Disclosure Statement

 Katie Stabi has no relevant financial relationship(s) with ineligible companies to disclose.
 and

 None of the planners for this activity have relevant financial relationships with ineligible companies to disclose.

Learning Objectives

At the completion of this activity, the participant will be able to:

- 1. Identify recent changes in state and federal laws and rules which impact pharmacy practice in Ohio;
- 2. Describe the effect of recent law and rule changes on the practice of pharmacy;
- 3. Discuss implementation strategies for law and rule compliance; and
- 4. Review relevant board notices and publications.

Compounding

OAC 4729:7-1-01 Compounding References

- Effective 3/31/21
 - USP <795>, USP <797>, and USP <800> means USP 43-NF 38, or any official supplement thereto (March 10, 2020)
- Comments for proposed changes were due 10/24/23
 - Has been filed with CSI
 - Implementation 1 year from effective date
 - Permits Board to grant extensions

R-2024-0291

Enforcement of USP 795 and USP 797

To permit licensees to begin the transition to the newly published Chapters of USP 795 and USP 797 (effective November 1, 2023), the Board will not take administrative action against a licensee if the licensee is found to be in compliance with the latest version of USP 795 and USP 797.

This authorization shall remain in effect until the rules enforcing these new chapters are made effective.

OAC 4729:7-2-03 Drugs Compounded in a Pharmacy

Product Quality Issue

- Any incident that causes the compounded drug preparation or its labeling to be mistaken for, or applied to, another article;
- Contamination of the compounded drug preparation, including but not limited to mold, fungal, bacterial, or particulate contamination; or
- Any significant chemical, physical, or other change or deterioration of the dispensed compounded drug preparation within the compounded drug preparation's assigned beyonduse date.

Report within 72 hours upon discovery

Examples

- Incorrect compounded concentration
- Particulates in compound (e.g., coring)
- Precipitation of compound
- Misbranded compounded product (e.g., biosimilar)

Reporting Form

Name of Compounding Pharmacy

State of Ohio Board of Pharmacy Compounding Product Quality Reporting Form (Rev. 6/2021)

Ohio TDDD License No.

Street Address	City		State	Zip		
Contact E-mail		Telepho	one No. (XXX)	xxx-xxxx		
Product Quality Report						
1. Product Description						
Name of Product	Lot # or Unique ID Beyond Use Date					
Product Components/Ingredients		Quantity of Compounded Product				
	·					
2. Type of Product Quality I	ssue (select a	II the apply):				
Any incident that causes the compounded drug preparation or its labeling to be mistaken for, or applied to, another article;						
Contamination of the com mold, fungal, bacterial, or				limited to		
Any significant chemical, I dispensed compounded di preparation's assigned be	rug preparation			he		
3. Date Product Quality Issu	ue Occurred	4. Issue Disc	overy Date			
5. State Where Product was Dispensed						

5. Have there been any adverse events reported by patients/customers?							
7. Has this issue be	een reported to I	FDA?		,			
	La constante	-	0				
Yes (Date	Reported:)	No				
8. Detailed Descrip		uct Quality Issue	(if more space is n	eeded may			
include as a separate	attachment)						
9. Follow-Up Actions Following Discovery (if more space is needed may include as							
a separate attachment)							
	AND 4729. OF	THE OHIO REVISED	CODE THAT THE INF	ET FORTH IN CHAPTERS 2921. CORMATION PROVIDED IN THIS			
		FORM IS TRUE, CORRECT, AND COMPLETE.					
	Responsible I	Person Signature	Date	Printed Name			

Attestation must be signed by the Responsible Person in wet ink. This form must be scanned and submitted, along with any attachment, via email to:

compliance@pharmacy.ohio.gov

OAC 4729:7-3-07 Pharmacists conducting medication validation



Prescriber can delegate a pharmacist to perform medication validation ("final check") of a finished compounded drug preparation



Follow prescriber compounding record keeping requirements

Transmission, Issuance, and Processing of Prescriptions

OAC 4729:5-3-11 Transmission of outpatient prescriptions

Oral

Prescriber +/- prescriber agents first and last name

Written

- Signed by prescriber (i.e., wet-ink)
- Facsimile
 - Identification number of machine, prescriber name +/- agent's full name
 - Remain with patient records: "VOID" or "FAXED"

Electronic Prescription Transmission System

Electronic Prescription Transmission System

- Include the full name of the prescriber's agent
- Controlled substances must comply with 21 CFR 1311
- May not convert into computer-generated fax or scanned image, except for non-controls:
 - Board approved system
 - Closed system
 - Board approved third-party intermediary during a temporary telecommunication outage

Not Valid Methods

- Electronic signature
- Docusign
- Text messages
- Messaging systems
- Email

ORC 3719.05 Pharmacist may dispense controlled substances - prescriptions - sale of stock

Schedule II controlled substance shall be dispensed only upon an electronic prescription

A pharmacist who receives a faxed, oral, or written prescription for a schedule II controlled substance is not required to verify that the prescription was issued under an exception.

ORC 3719.05 Pharmacist may dispense controlled substances - prescriptions - sale of stock



May be dispensed upon an oral prescription in emergency situations



May dispense upon a written prescription if there is a temporary technical, electrical, or broadband failure prevents the pharmacist from dispensing



May be dispensed upon a written prescription if it was issued as described in division (C) of ORC 3719.06.

Section 3719.06 Authority of licensed health professional

Prescriber may issue a written schedule II controlled substance prescription if any of the following apply:

- Temporary technical, electrical, or broadband failure occurs
- Issued for a nursing home resident or hospice care patient
- Prescriber is employed by or under contract with the same entity that operates the pharmacy
- Prescriber issues not more than 50 prescriptions/year
- Prescriber is a veterinarian

Section 3719.06 Authority of licensed health professional

Prescriber may issue a written schedule II controlled substance prescription if any of the following apply:

- Electronic prescription cannot be issued in a timely manner and the patient's medical condition is at risk
- Prescription issued from a health care facility, which may include an emergency department, and determines an electronic prescription would
 - Be impractical for the patient or
 - Cause a delay that may adversely impact the patient's medical condition

21 CFR Part 1306



Transfer of electronic prescriptions for schedules II–V controlled substances between registered retail pharmacies for initial filling, upon request from the patient, on a one-time basis



Authorized refills are to be transferred with original prescription




Must remain in its electronic form

Updates



OAC 4729:3-2-08 Verification of registration and certification





Certification from organization at least every 24 months

Registered Pharmacy Technicians

- Continuing education: 10 contact hours
 - April 1, 2022 March 31, 2024
 - CPE monitor account from NABP
 - 2 hours pharmacy jurisprudence
 - 2 hours patient or medication safety
- Renewal opened January 31, 2024
 - New registration expires 3/31/26
- Were permitted to upgrade to certified pharmacy technician

OARRS

New NarxCare functionality

Updated Overdose Risk Score

- Unintentional overdose risk scoring model
- Presentation of key contributing factors to the model's calculation

Fraudulent Promethazine Prescriptions

- Often phoned in or faxed
- If suspicious call or fax, contact:
 - Local law enforcement
 - Notify Board of Pharmacy



OAC 4729:5-5-08 Prospective drug utilization review



Based upon information obtained during a prospective drug utilization review, a pharmacist shall use professional judgment when making a determination about the legitimacy of a



A pharmacist shall not dispense a prescription of doubtful, questionable, or suspicious origin.

Fentanyl Test Strips

- SOBP partnered with Office of Governor Mike DeWine, RecoveryOhio, the Ohio Department of Mental Health and Addiction Services, and the Ohio Department of Health
- What can be ordered:
 - 2 boxes/order to Ohio TDDD
 - Educational Handouts
 - Pharmacies only: Naloxone patient counseling
- Order:

https://www.surveymonkey.com/r/FTSORDER

HOW TO TEST YOUR DRUGS

USING FENTANYL TEST STR



1. Put the drugs you are testing in a small, unused co

The more of your drugs you test, the more reliable the results will be.




2. Add water to your drugs and mix them up.

For 10 milligrams (mg) of:

- Meth, MDMA and ecstasy, use 1 teaspoon of water.
- Other drugs, like heroin, cocaine, crack, ketamine ar pills from nonmedical sources, use a half teaspoon of

10 mg is enough to cover Abraham Lincoln's hair on a penny or fill a standard microscoop.









Tips for testing your drugs:

- Do not use test strips more than once.
- Finely crush pills and tablets, add water to t powder mix thoroughly. If you do not want the entire pill, break it in half and test a porti the middle.



3. Place the strip in the water for 15 seconds.

Hold test strip at solid blue end, insert the wavy end in for 15 seconds.

Instructions Continued





Scan here for vid instructions (BTN Rapid Strips):

USING FENTANYL TEST STRIPS




4. Place the strip down flat and wait 5 minutes.

After waiting at least 5 minutes, look at the strip in full light. Do not attempt to read results after 10 minutes.




5. Read the results.


Positive test: If you are not planning to use fentanyl, avoid using the drugs, or start low and go slow.



Invalid test: Retest your drugs with a new strip.







What else can I do to lower my risk of overdose?

No drug is completely safe and there is always a risk of overdose. Try using the following tips:

- Use drugs with other people, take turns, and avoid sharing needles and other devices.
- . Go slow by taking small amounts and waiting in between use.
- Get naloxone and use it if there is an overdose. Naloxone can be obtained at your local pharmacy or can be obtained free-of-charge through the mail by visiting: naloxone.ohio.gov
- Contact 988: If you or someone you know is experiencing a non-life-threatening mental health or addiction-related crisis (thoughts of suicide, emotional distress, or substance use/addiction) call, chat, or text 988 for free, 24/7, confidential support.









Overdose Risk Factors & Prevention

Opioids include both illicit fentanyl and heroin as well as prescription medications used to treat pain such as morphine, codeine, methadone, oxycodone (Oxycontin, Percodan, Percocet), hydrocodone (Vicodin, Lortab, Norco), fentanyl (Duragesic, Fentora), hydromorphone (Dilaudid, Exalgo), and buprenorphine (Subutex, Suboxone). The following are some common risk factors for opioid overdose as well as some prevention strategies:

Mixing Drugs

Many overdoses occur when people mix heroin or prescription opioids with alcohol and/or benzodiazepines. Alcohol and benzodiazepines (Xanax, Klonopin, Ativan and Valium) are particularly dangerous because, like opioids, these substances impact an individual's ability to breathe. Avoid mixing opioids with other drugs or alcohol. If prescribed an opioid and a benzodiazepine by a prescriber, take only as directed.

Tolerance

Tolerance is your body's ability to process a drug. Tolerance changes over time so that you may need more of a drug to feel its effects. Tolerance can decrease rapidly when someone has taken a break from using an opioid. When someone loses tolerance and then takes an opioid again, they are at-risk for an overdose, even if they take an amount that caused them no problem in the past. If you are using opioids after a period of abstinence, start at a lower dose.

Physical Health

Your physical health impacts your body's ability to manage opioids. Since opioids can impair your ability to breathe, if you have asthma or other breathing problems you are at higher risk for an overdose. Individuals with liver (hepatitis), kidney problems, and those who are HIV-positive are also at an increased risk of an overdose.

Previous Overdose

A person who has experienced a nonfatal overdose in the past has an increased risk of a fatal overdose in the future. To prevent a fatal overdose, teach your family and friends how to recognize and

How do I know if someone is overdosing?

If someone takes more opioids than their body can handle, they can pass out, stop breathing, and die. An opioid overdose can take minutes or even hours to occur.

A person who is experiencing an overdose may have the following symptoms:

- Slow breathing (less than 1 breath every 5 seconds) or no breathing.
- Vomiting.
- · Face is pale and clammy.
- Blue lips, fingernails, or toenails.
- Slow, erratic, or no pulse.
- Snoring or gurgling noises while asleep or nodding out.
- No response when you yell the person's name or rub the middle of their chest with your knuckles.

An overdose is a MEDICAL EMERGENCY! Call 9-1-1 immediately



Overdose Recognition and Response Guide



A GUIDE FOR PATIENTS AND CAREGIVERS

State of Ohio Board of Pharmacy

Steven W. Schierholt

What is naloxone?

Naloxone (Narcan) is a prescription medication that can reverse an overdose that is caused by an opioid drug. When administered during an overdose, naloxone blocks the effects of opioids on the brain and restores breathing. It can be given as an injection into a muscle or as a nasal spray.

Naloxone has no potential for abuse. If it is given to a person who is not experiencing an opioid overdose, it is harmless. If naloxone is administered to a person who is experiencing an opioid overdose, it will produce withdrawal symptoms. Naloxone does not reverse overdoses that are caused by non-opioid drugs.

IMPORTANT: Naloxone should be stored at room temperature and away from light. Naloxone can freeze at low temperatures. If this happens, the medication may not work as intended.

Where to Get Help



Ohio Department of Mental Health and Addiction Services Treatment Referral Line (8am-6pm M-F) 1-877-275-6364

RecoveryOhio - How to Get Help www.pharmacy.ohio.gov/GetHelp

Substance Abuse & Mental Health Services Administration Treatment Locator

https://findtreatment.gov/

How to respond to an overdose

- Try to wake the person up by yelling their name and rubbing the middle of their chest with your knuckles (sternum rub).
- **2.** Call 9-1-1. Indicate the person has stopped breathing or is struggling to breathe.
- **3.** Make sure nothing is in the person's mouth that could be blocking their breathing. If breathing has stopped or is very slow, begin rescue breathing.

4. Give Rescue Breathing

Step 1: Tilt their head back, lift chin, pinch nose shut.


- **Step 2:** Give 1 slow breath every 5 seconds. Blow enough air into their lungs to make their chest rise.
- Use naloxone and continue rescue breathing at one breath every 5 seconds.
- **6.** If the person begins to breathe on their own, put them on their side so they do not choke on their vomit. Continue to monitor their breathing and perform rescue breathing if respirations are below 10 breaths a minute. If vomiting occurs, manually clear their mouth and nose.
- **7.** If the person does not respond by waking up, to voice or touch, or start breathing normally within 2-3 minutes, another dose of naloxone should be given.
- 8. Stay with the person until EMS arrives.

*Please be advised that there are other naloxone formulations available. Ohio law requires patients to be trained on the formulation of naloxone being dispensed. Pharmacists must provide supplemental training materials if dispensing a formulation of naloxone not listed in this brochure.

How to give naloxone*:

NARCAN™ (4MG) and Kloxxado™ (8MG) Nasal Spray

- 1. Peel back the tab to open the nasal spray.
- 2. Hold the device with your thumb on the bottom of the plunger and your first and middle fingers on either side of the nozzle. Do not apply



any pressure until you are ready to give the dose.

- 3. Tilt the person's head back and provide support under the neck with your hand. Gently insert the tip of the nozzle into one nostril until your fingers on either side of the nozzle are against the bottom of the person's nose.
- Press the plunger firmly to give the dose of the medication. Remove the device from the nostril after giving the dose.
- **5.** If the person is unresponsive after 2 to 3 minutes, give an additional dose in the other nostril.

For a copy of the manufacturer's instructions visit: www.pharmacy.ohio.gov/NARnasal (NARCAN) www.pharmacy.ohio.gov/KLOnasal (Kloxxado)

ZIMHI™ (Naloxone HCI) Injection

- Press needle into outer thigh after twisting off needle cap.
- 2. Push the plunger until it clicks and hold for 2 seconds before removing the needle. The correct dose has been given if the plunger has been pushed all the way down and blocks part of the solution window. It is normal for most of the medicine to remain in the syringe after the dose has been injected.
- Pull the safety guard down using one hand with fingers behind the needle. Do this right after you give the injection.
- **4.** Place the used syringe into the blue case and close it. If the person is unresponsive after 2 to 3 minutes, give an additional dose using a new device.

For a copy of the manufacturer's instructions visit: www.pharmacy.ohio.gov/ZIMinject

OAC 4729:5-5-06 Labeling of drugs dispensed on prescription

Contact phone number of one of the following:

- Dispensing pharmacy
- Location where a pharmacist is employed/contracted that has full access to the dispensing pharmacy's patient records



OAC 4729:2-2-06 Statement of preceptor and practical experience affidavit

- Practical experience affidavits for a calendar year can be submitted at any time
 - Must be no later than one year after credit is earned
- Previously had to be by March 1

OAC 4729:1-5-02
Continuing
education
requirements for
pharmacists

- 30 hours
 - 2 pharmacy jurisprudence
 - 2 medication safety
- Initial licensure by exam or reciprocity does not have to complete CE for initial period

OAC 4729:1-5-01 Pharmacist continuing education - definitions

"Board approved pharmacy practice-specific specialty certification program" means:

- 1. The program is offered by the board of pharmacy specialties (BPS); or
- 2. The program is offered by the specialty pharmacy certification board (SPCB); or
- 3. A program approved by the board

OAC 4729:3-2-01 Registration procedures

- Permits pharmacy technician reciprocity
- Trainee registration is valid for 18 months
 - Can apply for reinstatement

OAC 4729:3-3-02 Approved pharmacy technician training programs

TDDD is responsible for providing employer-based training

Includes training of USP<800> and USP<825> for non-sterile and sterile compounding, as applicable

OAC 4729:7-2-03
Drugs
compounded in a pharmacy

Registered pharmacy technician may engage in sterile compounding

OAC 4729:3-3-03 Registered pharmacy technicians

May perform sterile compounding if:

- In process of studying to obtain certification
- Not engage in sterile compounding for longer than 18 months from date completed training
- TDDD is accountable for 18 month period

Register as certified pharmacy technician to continue compounding past 18 month period

Proposed Rules

Proposed Rules



Public Participation



Guide to Public Participation in the Rule-Making Process

Revised: 10/7/2019

Mission and Structure of the Board

The mission of the State of Ohio Board of Pharmacy is to act efficiently, consistently, and impartially in the public interest to pursue optimal standards of practice through communication, education, legislation, licensing, and enforcement.

The State of Ohio Board of Pharmacy is the single state agency in Ohio responsible for administering and enforcing laws governing the legal distribution of drugs. The Board consists of nine members who are appointed by the Governor for terms of four years. Eight of the members are licensed pharmacists who represent, to the extent practicable, each phase of pharmacy practice. One member represents the public.

Since the State of Ohio Board of Pharmacy is responsible for administering and enforcing the drug

https://www.pharmacy.ohio.gov/documents/lawsrules/proposedrules/guide%20to%20public%20participation%20in%20the%20rule-making%20process.pdf

Process

Step 1: Rules Review Committee

- Meets quarterly
- Proposed rules and 5-year review

Step 2: Approval for Filing by the Board

 Board approves filing with Common Sense Initiative (CSI) and then the Joint Committee on Agency Rule Review (JCARR)

Process

Step 3: File with CSI

- Permits public comment
- Usually 16 business days

Step 4: File with JCARR

Step 5: Public Hearing

Held 30-41 days after rules filed with JCARR

Step 6: JCARR Hearing

Process


Step 7: Rules Adoption

 Shall not be earlier than 10th day after it's been filed in its final form

Public Participation

- Initiate discussion: submit concerns
- Rule formulation: public Rules Review Committee
- CSI: comment period
- Public Rules Hearing
- JCARR Hearing

Timeline



JCARR Public Hearing 2/13/24

Rule Number	Туре	Tagline
4729:5-5-02	Rescind	Minimum standards for an outpatient pharmacy.
4729:5-5-02	New	Minimum Standards for the Operation of an Outpatient Pharmacy.
4729:5-5-02.1	New	Provision of Ancillary Services in an Outpatient Pharmacy.
4729:5-5-02.2	New	Mandatory Rest Breaks for Pharmacy Personnel.
4729:5-5-02.3	New	Requests for Additional Staff and Reports of Staffing Concerns in an Outpatient Pharmacy.
4729:5-5-02.4	New	Significant Delays in the Provision of Pharmacy Services.
4729:5-5-02.5	New	Outpatient Pharmacy Access Points.
4729:5-2-05	New	Notification of Accessible Services.

OAC 4729:5-5-02
Minimum
Standards for the
Operation of an
Outpatient
Pharmacy

"Ensure sufficient personnel are scheduled to work at all times in order to minimize fatigue, distraction, or other conditions which interfere with a pharmacist's ability to practice with reasonable competence and safety. Staffing levels shall not be solely based on prescription volume but shall consider any other requirements of the practice of pharmacy by pharmacy personnel during working hours."

OAC 4729:5-5-02.1 Provision of Ancillary Services in an Outpatient Pharmacy

Ancillary Services

Immunizations

Drug administration

Medication therapy management

Disease state management

Refill reminders

Not Ancillary Services

 Services provided by an outpatient pharmacy to patients upon discharge from an institutional facility

OAC 4729:5-5-02.1 Provision of Ancillary Services in an Outpatient Pharmacy

An outpatient pharmacy shall not establish any quotas relating to the provision of ancillary services.

"Quota" means a fixed number or formula related to the duties of pharmacy personnel, against which the pharmacy or its agent measures or evaluates the number of times either an individual performs tasks or provides services while on duty.

Quota Does Not Mean

A measurement of the revenue earned by a pharmacy not calculated in relation to, or measured by, the tasks performed, or services provided by pharmacy personnel.

Any evaluation or measurement of the competence, performance, or quality of care provided to patients of pharmacy personnel if the evaluation does not use quotas.

Any performance metric required by state or federal regulators.

OAC 4729:5-5-02.2 Mandatory Rest Breaks for Pharmacy Personnel



May not require pharmacy personnel to work >13 hours

Must allow at least 8 hours of off time between consecutive shifts

PHARMACIST may volunteer to work longer



Pharmacy personnel working >6 continuous hours/workday is allowed to take a 30-minute uninterrupted rest break

Pharmacist remains on premise unless:

- ≥2 Pharmacists working
- Pharmacy closes



Pharmacy shall not retaliate or discipline a pharmacist for refusing to work longer than 13 hours or pharmacy personnel that opt to take breaks

OAC 4729:5-5-02.3 Requests for Additional Staff and Reports of Staffing Concerns in an Outpatient Pharmacy

- Develop a process for pharmacy staff to communicate requests for additional staff or reports of staffing concerns
- A written response shall occur within 14 business days of submission
- Shall not retaliate or discipline a pharmacist who, in good faith, makes a request

OAC 4729:5-5-02.4 Significant Delays in the Provision of Pharmacy Services

"Significant delay" means a prescription that was submitted and not yet dispensed:

New: within 3 business days Refills not generated by auto-refill: withir 3 business days

Auto-refill program: within 5 business days



Receipt occurs on day new prescription is transmitted or submitted to pharmacy

Receipt occurs when refill is submitted or generated

Significant Delay is NOT:

Drug shortage or drug not available

Clarification needed

Prior authorization

Compounded drug


Prescription that is considered questionable, doubtful, or suspicious

Prescription that cannot be safely provided or may negatively impact care

Patient, prescriber, caregiver request

Transfer requested

Disaster (e.g., natural, loss of power, technology outage)





Transfer prescriptions to another pharmacy, upon patient consent



Increase pharmacy staff



Other strategy that is agreed upon by pharmacy and board



Triage lifesaving and lifesustaining medications

Auto-Refills


- Must be authorized by patient or patient's caregiver
- Maintain documentation of enrollment and date
- Consent may be captured electronically, verbally, or in writing
- Maintain record of consent in patient profile or another system
- Discontinue enrollment upon request

OAC 4729:5-5-02.5 Outpatient Pharmacy Access Points

- Pharmacy must have policy that permits a pharmacist to:
 - Limit provision of ancillary services
 - Limit pharmacy access points
- If no policy, pharmacy shall not override control of the pharmacist on duty
- Pharmacy shall not retaliate or discipline pharmacist who, in good faith, acts in accordance to rule

Contact the Board, Notices, and Publications

Pharmacy.ohio.gov



Contact



The State of Ohio Board of Pharmacy welcomes your comments, suggestions, and questions.

We can be reached at:


77 S High Street, 17th Floor Columbus, OH 43215-6126

Telephone: (614) 466-4143 **Fax:** (614) 752-4836

TTY/TDD Ohio Relay Service: 1 (800) 750-0750

Media Relations: (614) 705-1190

Click here to access our online complaint form.



Pharmacy.ohio.gov



File a Complaint STATE OF OHIO BOARD OF PHARMACY **COMPLAINT FORM**

Per section 4729.23 of the Ohio Revised Code, the identity of an individual submitting a complaint State of Ohio Board of Pharmacy is confidential. If, however, after review of the issues in the comp Board discovers jurisdiction is more appropriate with a different investigative body, the complaint information may be shared with another agency. Any agency receiving information from the Boar to the same confidentiality requirements.

Items marked with a * are required.			
Name of Complainant*			
Address*			
City*			
State*			
Zip Code*			
Home Phone*			
Business Phone			
Email Address*			
Re-enter Email*			
Incident Date*	6,		

is your complaint against a business such a	is a pnarmacy or nospital?*
○Yes	
●No	
Is your complaint against a person, such as OYes	a pharmacist, pharmacy technician, patient or prescriber?*
●No	
Does your complaint involve a specific pres	cription?*
No	
Oves our complaint involve an OARRS reproves No	ort?*
Have you made a complaint to any other g	Have you made a complaint to any other government agency, professional association, etc. about this matter?* O'res No
OYes	In your own words, with as much detail as possible, please state your complaint.*
	Maximum 8000 characters
	Were there any other witnesses or other persons who may have additional information about your complaint?* O'Yes
	SUBMIT COMPLAINT

Is your complaint against a business

Avoid Scammers in 2024

The State of Ohio Board of Pharmacy continues to learn that licensees are being targeted by scammers who claim to work for various governmental agencies (Board of Pharmacy, DEA, FBI, Department of Justice, etc.) to obtain money from the target. The Board strongly encourages licensees to be alert in 2024 to avoid scammers.

The scam involves phone calls, emails, and letters purporting to originate from various state and federal agencies, as well as faxes, that include allegations of drug trafficking and threats of suspension against the target's license.

Board of Pharmacy investigators will not ask for fine payment or personal/sensitive information over the phone and will never contact licensees via fax. As a reminder, administrative fines issued by the Board are not paid via gift cards or cryptocurrency.

If the Board of Pharmacy is conducting an investigation and that individual faces action against their license, they will receive an official notice of opportunity for a hearing either via certified mail or by personal service.

If you are contacted by a scammer, please report this information using the Board's online complaint form: www.pharmacy.ohio.gov/complaint. Additionally, reports should be made to your local law enforcement agency.

If you receive any suspicious calls or correspondence purporting to be the from the Board of Pharmacy, we encourage you to call (614-466-4143) or email (contact@pharmacy.ohio.gov) the Board to confirm its legitimacy.

Verify Messages



Verify Messages

VERIFY MESSAGES:

Most Recent

- > 2024-02-07 Request for Comment Schedule I-V Controlled Substances
- > 2024-02-05 Phishing Tips to Avoid Getting Hooked
- > 2023-01-31 e-News January 2024
- > 2024-02-01 NABP February 2024 Ohio Newsletter
- > 2024-01-26 Rules for Stakeholder Comment
- > 2024-01-19 Licensee Alert Fraudulent Promethazine Prescriptions
- > 2024-01-11 Registered Pharmacy Technician Renewal will Open January 31st
- > 2024-01-09 Extension of Expiration of Animal Euthanasia Solution is Being Rescinded
- > 2024-01-05 Avoid Scammers in 2024
- > 2023-12-19 Rules for Stakeholder Comment (Updated)
- > 2023-12-18 Registered Pharmacy Technician Renewal and Continuing Education Requirements
- > 2023-12-12 Rules for Stakeholder Comment
- > 2023-12-01 E-News December 2023
- > 2023-11-7 Continuous Quality Improvement and Duty to Report Rules
- > 2023-10-24 Board of Pharmacy Adds Nalmefene as an Overdose Reversal Drug
- > 2023-10-23 Registered Technician Renewal 2024
- > 2023-10-17 2023 Loss Prevention Roundtable
- > 2023-10-12 Request for Comment Accessible Pharmacy Services
- > 2023-10-04 Proposed Compounding Rules USP 797 and USP 795
- > 2023-08-25 E-News August 2023
- > 2023-08-24 988 Suicide and Crisis Lifeline

References

- https://www.pharmacy.ohio.gov/documents/lawsrules/proposedrules/guide%20to% 20public%20participation%20in%20the%20rule-making%20process.pdf
 https://www.registerofohio.state.oh.us/pdfs/4729/5/5/4729\$5-5-02_PH_OF_N_RU_20240104_1522.pdf
- https://www.registerofohio.state.oh.us/pdfs/4729/5/5/4729\$5-5-I_PH_RV_N_RU_20240207_1209.pdf
- https://www.registerofohio.state.oh.us/pdfs/4729/5/5/4729\$5-5-02\$2 PH OF N RU 20240104 1522.pdf
- https://www.registerofohio.state.oh.us/pdfs/4729/5/5/4729\$5-5-02\$3 PH OF N RU 20240104 1522.pdf
- https://www.registerofohio.state.oh.us/pdfs/4729/5/5/4729\$5-5-02\$4 PH OF N RU 20240104 1522.pdf
- https://www.registerofohio.state.oh.us/pdfs/4729/5/5/4729\$5-5-02\$5 PH OF N RU 20240104 1522.pdf
- https://codes.ohio.gov/ohio-administrative-code/rule-4729:7-1-01
- https://codes.ohio.gov/ohio-administrative-code/rule-4729:7-3-06
- https://www.pharmacy.ohio.gov/documents/pubs/messages/2024-02-01%20nabp%20february%202024%20ohio%20newsletter.pdf
- https://www.govinfo.gov/content/pkg/FR-2023-07-27/pdf/2023-15847.pdf? hsmi=293990451&_hsenc=p2ANqtz-wE53nUNiDs5eQgPa_AqsN2DgCsVtc7CkRjNQgz1NL0ZyY9B34NMXkIXXlFWZMDsJ 6s7eGlxGAq1TewcMDO6DolpXW4y9g4n4o8b 7HLKR20yOil8

References

- https://codes.ohio.gov/ohio-administrative-code/rule-4729:5-5-08
- https://codes.ohio.gov/ohio-administrative-code/rule-4729:5-3-11
- https://codes.ohio.gov/ohio-revised-code/section-3719.05
- https://codes.ohio.gov/ohio-revised-code/section-3719.06
- https://www.registerofohio.state.oh.us/pdfs/4729/5/5/4729\$5-5-06 PH FF A RU 20240226 1319.pdf
- https://www.registerofohio.state.oh.us/pdfs/4729/2/2/4729\$2-2-06 PH FF A RU 20240226 1325.pdf
- https://www.registerofohio.state.oh.us/pdfs/4729/1/5/4729\$1-5-01 PH FF A RU 20240223 1255.pdf
- https://www.registerofohio.state.oh.us/pdfs/4729/1/5/4729\$1-5-02 PH FF A RU 20240223 1255.pdf
- https://www.registerofohio.state.oh.us/pdfs/4729/3/2/4729\$3-2-01 PH FF A RU 20240227 1542.pdf
- https://www.registerofohio.state.oh.us/pdfs/4729/3/3/4729\$3-3-02 PH FF A RU 20240226 1328.pdf
- https://www.registerofohio.state.oh.us/pdfs/4729/3/3/4729\$3-3-03 PH FF A RU 20240226 1328.pdf
- https://www.registerofohio.state.oh.us/pdfs/4729/7/2/4729\$7-2-03 PH FF A RU 20240226 1331.pdf

Need More Information?

Katie Stabi, PharmD, BCPS, RPh Katie.stabi@pharmacy.ohio.gov



